Patents by Inventor Biswanath De
Biswanath De has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220098210Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quindoline (or similar) structure which function as stabilizers of G-quadruplex (G4) formation, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer), and other conditions mediated by G4 stabilization.Type: ApplicationFiled: January 29, 2020Publication date: March 31, 2022Inventors: Laurence Hurley, Biswanath De, Venkateshwar R. Chappeta, Tracy A. Brooks, Vijay Gokhale, Cynthia Miranti, Elsa Reyes Reyes
-
Patent number: 7449474Abstract: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: GrantFiled: April 21, 2005Date of Patent: November 11, 2008Assignee: The Procter & Gamble CompanyInventors: Todd Andrew Brugel, Jennifer Anne Townes, Michael Philip Clark, Mark Sabat, Adam Golebiowski, Biswanath De, Stephen Matthew Berberich, Gregory Kent Bosch
-
Patent number: 7402589Abstract: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: GrantFiled: April 21, 2005Date of Patent: July 22, 2008Assignee: The Procter & Gamble CompanyInventors: Todd Andrew Brugel, Jennifer Anne Townes, Michael Philip Clark, Mark Sabat, Adam Golebiowski, Biswanath De
-
Publication number: 20080139588Abstract: The present invention relates to 2,6,7-substituted pyrrolo[2,3-d]pyrimidines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,6,7-substituted pyrrolo[2,3-d]pyrimidines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: ApplicationFiled: November 26, 2007Publication date: June 12, 2008Inventors: Michael Philip Clark, Todd Andrew Brugel, Mark Sabat, Adam Golebiowski, Roger Gunnard Bookland, Biswanath De
-
Patent number: 7319102Abstract: The present invention relates to 2,6,7-substituted pyrrolo[2,3-d]pyrimidines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,6,7-substituted pyrrolo[2,3-d]pyrimidines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: GrantFiled: December 7, 2004Date of Patent: January 15, 2008Assignee: The Procter & Gamble CompanyInventors: Michael Philip Clark, Todd Andrew Brugel, Mark Sabat, Adam Golebiowski, Roger Gunnard Bookland, Biswanath De
-
Patent number: 7256196Abstract: The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,8,9-substituted purines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: GrantFiled: December 7, 2004Date of Patent: August 14, 2007Assignee: The Procter & Gamble CompanyInventors: Mark Sabat, Michael Philip Clark, Todd Andrew Brugel, Adam Golebiowski, John Charles Van Rens, Biswanath De
-
Patent number: 7138395Abstract: The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula: X is —CH2—, —O— or —NR9—; R is a carbocyclic or heterocyclic ring; R1 is a cysteine trap; R2a, R2a?, R2b, and R2b? are each independently hydrogen, C1–C4 alkyl, C1–C4 alkoxy, and mixtures thereof; or R2a? and R2b? can taken together to form a double bond; R9 is hydrogen or a unit having the formula -L2-R10; L is the same as defined herein above; R10 is hydrogen; substituted or unsubstituted C1–C6 linear; branched, or cyclic hydrocarbyl; substituted or unsubstituted aryl; substituted or unsubstituted C1–C9 heterocyclic; and substituted or unsubstituted heteroaryl.Type: GrantFiled: June 9, 2003Date of Patent: November 21, 2006Assignee: The Procter & Gamble CompanyInventors: Steven Victor O'Neil, Michael Christopher Laufersweiler, Yili Wang, Kofi Abeka Oppong, David Lindsey Soper, John August Wos, Biswanath De, Thomas Prosser Demuth, Jr.
-
Patent number: 7087615Abstract: The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R comprises ethers or amines; R1 is: a) substituted or unsubstituted aryl; or b) substituted or unsubstituted heteroaryl; each R2 unit is independently selected from the group consisting of: a) hydrogen; b) —(CH2)jO(CH2)nR8; c) —(CH2)jNR9aR9b; d) —(CH2)jCO2R10; e) —(CH2)jOCO2R10 f) —(CH2)jCON(R10)2; g) —(CH2)jOCON(R10)2; h) two R2 units can be taken together to form a carbonyl unit; i) and mixtures thereof; R8, R9a, R9b, and R10 are each independently hydrogen, C1–C4 alkyl, and mixtures thereof; R9a and R9b can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R10 units can be take together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; j is an index from 0 to 5,Type: GrantFiled: October 20, 2003Date of Patent: August 8, 2006Assignee: The Procter & Gamble CompanyInventors: Michael Philip Clark, Matthew John Laufersweiler, Biswanath De, Michael John Janusz
-
Patent number: 7041696Abstract: The present invention relates to interleukin-1? converting enzyme inhibitors having the formula: R is a carbocyclic or heterocyclic ring; R1 is a cysteine trap; R2a, R2a?, R2b, and R2b? are each independently hydrogen, C1–C4 alkyl, C1–C4 alkoxy, and mixtures thereof; or R2a? and R2b? can taken together to form a double bond; L and L1 are linking groups having the formula: T is selected from the group consisting of: i) —NR6—; ii) —O—; iii) —NR6S(O)2—; iv) —S(O)2NR6—; and v) mixtures thereof; R6 is hydrogen, substituted or unsubstituted C1–C20 linear, branched, or cyclic alkyl, C6–C20 aryl, C7–C20 alkylenearyl, and mixtures thereof; the indices w, w1, and w2 are each independently 0 or 1; i) hydrogen; ii) C1–C4 linear, branched, and cyclic alkyl; iii) R3a and R3b or R4a, and R4b can be taken together to form a carbonyl unit; iv) two R3a or two R3b units from adjacent carbon atoms or two R4a or two R4b units from adjacent carbon atoms can be taken together to form a double bond; and v) mixtures thereof;Type: GrantFiled: June 9, 2003Date of Patent: May 9, 2006Assignee: The Procter & Gamble CompanyInventors: John August Wos, David Lindsey Soper, Steven Victor O'Neil, Yili Wang, Kofi Abeka Oppong, Michael Christopher Laufersweiler, Jian Chen, Biswanath De, Thomas Prosser Demuth, Jr.
-
Patent number: 7001899Abstract: The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula: wherein each X is independently selected from: i) —C(W)2—; ii) —C(O)—; iii) —NR2—; iv) —S—; v) —S(O)—; vi) —S(O)2—; vii) two units, one from each adjacent X unit, can be taken together to form a substituted or unsubstituted double bond having the formula —CW?CW—; wherein each W is hydrogen of a unit having the formula —(L2)j—R2, the index j is 0 or 1; R is a carbocyclic or heterocyclic aryl ring; R1 is a cysteine trap; each R2 is independently a suitable substituent; and L, L1, and L2 are linking units.Type: GrantFiled: June 9, 2003Date of Patent: February 21, 2006Assignee: The Procter & Gamble CompanyInventors: John August Wos, Yili Wang, Kofi Abeka Oppong, Steven Victor O'Neil, Michael Christopher Laufersweiler, David Lindsey Soper, Biswanath De, Thomas Prosser Demuth, Jr.
-
Publication number: 20050245555Abstract: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: ApplicationFiled: April 21, 2005Publication date: November 3, 2005Applicant: The Procter & Gamble CompanyInventors: Todd Brugel, Jennifer Townes, Michael Clark, Mark Sabat, Adam Golebiowski, Biswanath De
-
Publication number: 20050239811Abstract: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.Type: ApplicationFiled: April 21, 2005Publication date: October 27, 2005Applicant: The Procter & Gamble CompanyInventors: Todd Brugel, Jennifer Townes, Michael Clark, Mark Sabat, Adam Golebiowski, Biswanath De, Stephen Berberich, Gregory Bosch
-
Patent number: 6949545Abstract: Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): where R1, R2, R3, n, A, E, X, G, G?, M and Z have the meanings described in the specification and the claims, as well as optical isomers, diastereomers and enantiomers of Formula I, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating metalloprotease-related maladies using the compounds or the pharmaceutical compositions.Type: GrantFiled: September 13, 2002Date of Patent: September 27, 2005Assignee: The Procter & Gamble CompanyInventors: Stanislaw Pikul, Norman Eugene Ohler, Neil Gregory Almstead, Steven Karl Laughlin, Michael George Natchus, Biswanath De, Paul Mitchell Hershberger
-
Patent number: 6919346Abstract: Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.Type: GrantFiled: December 2, 2003Date of Patent: July 19, 2005Assignee: The Procter & Gamble CompanyInventors: Michael Philip Clark, Jane Far-Jine Djung, Steven Karl Laughlin, Joshua Spector Tullis, Michael George Natchus, Biswanath De
-
Publication number: 20050154019Abstract: The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: ApplicationFiled: December 3, 2004Publication date: July 14, 2005Inventors: Michael Natchus, Biswanath De, Stanislaw Pikul, Neil Almstead, Roger Bookland, Yetunde Taiwo, Menyan Cheng
-
Publication number: 20050137248Abstract: The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: ApplicationFiled: February 16, 2005Publication date: June 23, 2005Inventors: Michael Natchus, Biswanath De, Stanislaw Pikul, Neil Almstead, Roger Bookland, Yetunde Taiwo, Menyan Cheng
-
Publication number: 20050101567Abstract: The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: ApplicationFiled: December 3, 2004Publication date: May 12, 2005Inventors: Michael Natchus, Biswanath De, Stanislaw Pikul, Neil Almstead, Roger Bookland, Yetunde Taiwo, Menyan Cheng
-
Patent number: 6872742Abstract: The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: GrantFiled: July 1, 2002Date of Patent: March 29, 2005Assignee: The Procter & Gamble CompanyInventors: Michael George Natchus, Biswanath De, Stanislaw Pikul, Neil Gregory Almstead, Roger Gunnard Bookland, Yetunde Olabisi Taiwo, Menyan Cheng
-
Patent number: 6858628Abstract: The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: GrantFiled: December 3, 2002Date of Patent: February 22, 2005Assignee: The Proctor & Gamble CompanyInventors: Michael George Natchus, Biswanath De, Stanislaw Pikul, Neil Gregory Almstead, Roger Gunnard Bookland, Yetunde Olabisi Taiwo, Menyan Cheng
-
Patent number: RE43372Abstract: Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.Type: GrantFiled: June 5, 2009Date of Patent: May 8, 2012Assignee: Duke UniversityInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De